DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Jan H.M. Schellens, Annemieke Cats et al.|The Lancet Oncology|2018

Cited by 419